PD31-08 HEPARIN THROMBOPROPHYLAXIS IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD31-08 HEPARIN THROMBOPROPHYLAXIS IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES Erica Ai-Li, Kaveh Farrohki, Max Zhang, Juliano Offerni, Patrick Luke, and Alp Sener Erica Ai-LiErica Ai-Li More articles by this author , Kaveh FarrohkiKaveh Farrohki More articles by this author , Max ZhangMax Zhang More articles by this author , Juliano OfferniJuliano Offerni More articles by this author , Patrick LukePatrick Luke More articles by this author , and Alp SenerAlp Sener More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003324.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Thrombosis is a leading causes of pancreas graft loss after simultaneous pancreas kidney (SPK), pancreas after kidney (PAK), and pancreas transplant alone (PTA). There remains no standardized thromboprophylaxis protocol. The aim of this systematic review and meta-analysis is to evaluate the impact of heparin thromboprophylaxis on the incidence of pancreas thrombosis, pancreas graft loss, bleeding, and secondary outcomes in SPK, PAK, and PTA. METHODS: Following PRISMA guidelines, we systematically searched BIOSIS®, PubMed®, Cochrane Library®, EMBASE®, MEDLINE®, and Web of Science® on April 21, 2021. Primary peer-reviewed studies that met inclusion criteria were included. Two methods of quantitative synthesis were performed to account for comparative and non-comparative studies. RESULTS: We included 11 studies, comprising of 1122 patients in the heparin group and 236 patients in the no-heparin group. When compared to the no-heparin control, prophylactic heparinization significantly decreased the risk of early pancreas thrombosis and pancreas loss for SPK, PAK and PTA without increasing the incidence of bleeding or acute return to the operating room. CONCLUSIONS: This study is the first to highlight that heparin thromboprophylaxis yields an approximate two-fold reduction in both pancreas thrombosis and pancreas loss for SPK, PAK and PTA. We report the dosage, frequency, and duration of heparin administration to consolidate the available evidence. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e903 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Erica Ai-Li More articles by this author Kaveh Farrohki More articles by this author Max Zhang More articles by this author Juliano Offerni More articles by this author Patrick Luke More articles by this author Alp Sener More articles by this author Expand All Advertisement PDF downloadLoading ...